Literature DB >> 12014654

Expression of survivin in CIN and invasive squamous cell carcinoma of uterine cervix.

Han-Seong Kim1, Katsuya Shiraki, Sung-Hye Park.   

Abstract

BACKGROUND: Survivin is a novel member of the inhibitors of apotosis proteins (IAP). To evaluate the possible role of survivin in tumorigenesis of CIN (cervical intraepithelial neoplasia) and invasive squamous cervical carcinoma of the uterine cervix (SCC), the expression of survivin was studied. MATERIALS AND
RESULTS: In 41 CIN and SCC tissues, the expression of survivin, Fas-ligand, Fas and bcl-2 was studied by immunohistochemistry. Survivin expression tended to increase along with tumor progression; low-grade squamous intra-epithelial lesions (HSIL, CIN I), 66.7%, high-grade squamous epithelial lesions (HSIL, CIN II and III), 87.5% and SCC, 100% with a statistical significance (p<0.019). Alteration of Fas-ligand, Fas and bcl-2 expression was detected in 12.5%-25% of HSIL and in 7.7%-30.8% of SCC but no abnormal expression was found in LSIL.
CONCLUSION: Survivin expression seems to be more closely related to the progression of CIN and SCC compared to Fas-ligand, Fas and bcl-2.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12014654

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  11 in total

1.  Clinicopathological significance of survivin expression in patients with cervical cancer: A systematic meta-analysis.

Authors:  Yibing Fan; Juan Chen
Journal:  Bioengineered       Date:  2017-01-04       Impact factor: 3.269

2.  Expression of survivin, cyclinD1, p21(WAF1), caspase-3 in cervical cancer and its relation with prognosis.

Authors:  Shi Lu; Baohua Zhang; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

3.  Survivin promoter polymorphism and cervical carcinogenesis.

Authors:  A A Borbély; M Murvai; K Szarka; J Kónya; L Gergely; Z Hernádi; G Veress
Journal:  J Clin Pathol       Date:  2006-05-19       Impact factor: 3.411

4.  Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker?

Authors:  Jaya Nigam; Abhijit Chandra; Hasan Raza Kazmi; Devendra Parmar; Devendra Singh; Vishal Gupta; Noushif M
Journal:  Tumour Biol       Date:  2014-06-17

Review 5.  Gene discovery in cervical cancer : towards diagnostic and therapeutic biomarkers.

Authors:  Cara M Martin; Louise Kehoe; Cathy O Spillane; John J O'Leary
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 6.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

7.  A sandwich SERS immunoassay platform based on a single-layer Au-Ag nanobox array substrate for simultaneous detection of SCCA and survivin in serum of patients with cervical lesions.

Authors:  Yifan Liu; Menglin Ran; Yue Sun; Yongxin Fan; Jinghan Wang; Xiaowei Cao; Dan Lu
Journal:  RSC Adv       Date:  2021-11-16       Impact factor: 4.036

8.  Inhibitors of apoptosis proteins in human cervical cancer.

Authors:  Magali Espinosa; David Cantú; Norma Herrera; Carlos M Lopez; Jaime G De la Garza; Vilma Maldonado; Jorge Melendez-Zajgla
Journal:  BMC Cancer       Date:  2006-02-27       Impact factor: 4.430

Review 9.  Role of survivin and its splice variants in tumorigenesis.

Authors:  F Li
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

10.  Evaluation of survivin splice variants in pituitary tumors.

Authors:  Joanna Waligórska-Stachura; Mirosław Andrusiewicz; Nadia Sawicka-Gutaj; Marta Kubiczak; Anna Jankowska; Włodzimierz Liebert; Agata Czarnywojtek; Ryszard Waśko; Al Ricardo Blanco-Gangoo; Marek Ruchała
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.